Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Anixa Biosciences, Inc.NASDAQ: ANIX
Depreciation & Amortization · Q2 FY2026 · quarter ended Apr 2026
Depreciation & amortization outflow shrinks to $0
Q2 FY2026 depreciation & amortization was $0, compared with $9K a year earlier. Trailing-twelve-month depreciation & amortization was $75K.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $18.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- (107K) USD
- Year-over-year change
- -389.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (107K) | -389.2% |
| FY2024 | 2024-10-31 | 37K | -19.6% |
| FY2023 | 2023-10-31 | 46K | +9.5% |
| FY2022 | 2022-10-31 | 42K | -30.0% |
| FY2021 | 2021-10-31 | 60K | — |
Depreciation & Amortization vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 depreciation & amortization of $75K is the 6th largest of the 10 companies compared; the peer median is $80.68K.
- Its year-over-year change of +150.0% is the 2nd highest of 8, against a peer median of -22.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M | -44.0% | +24.3% | 6.0% | |
| LTM Mar 2026 | $4.89M | -22.2% | +22.5% | 32.5% | |
| LTM Mar 2026 | $2.99M | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $880K | +391.6% | — | — | |
| LTM Mar 2026 | $80.68K | — | -42.4% | — | |
| LTM Apr 2026 | $75K | +150.0% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +130.4% | +136.6% | 0.4% |
| LTM Mar 2026 | $29K | -29.3% | -22.3% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding ANIX) | $80.68K | -22.2% | +2.1% | 3.2% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Depreciation & Amortization | 60K | 42K | 46K | 37K | (107K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.5M | 6M | 4.42M | 4.42M | 3.68M |
| Change in Working Capital | 78K | 485K | (1.06M) | 526K | 152K |
| Accounts Receivables | 0 | (29K) | (224K) | 97K | 173K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (96K) | 129K | (59K) | 319K | (360K) |
| Other Working Capital | 174K | 385K | (777K) | 110K | 339K |
| Other Non-Cash Items | 549K | 752K | 313K | 380K | 129K |
| Operating Cash Flow | (4.94M) | (6.49M) | (6.21M) | (7.34M) | (7.17M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (16.5M) | (22.49M) | (44.41M) | (63.77M) | (44.36M) |
| Sales of Investments | 12.54M | 11.76M | 38.81M | 68.05M | 49.23M |
| Other Investing Activities | 35K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.92M) | (10.73M) | (5.6M) | 4.28M | 4.87M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 31.13M | 0 | 0 | 2.96M | 2.28M |
| Common Stock Repurchased | 0 | 0 | 0 | (6K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 440K | 452K | 366K | 466K | 0 |
| Financing Cash Flow | 31.57M | 452K | 366K | 3.42M | 2.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 22.71M | (16.77M) | (11.45M) | 356K | (27K) |
| Free Cash Flow | (4.94M) | (6.49M) | (6.21M) | (7.34M) | (7.17M) |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.